INDEPENDENT NEWS

Cablegate: Extrancheck: Pre-License Check: New a-Ikor Limited

Published: Thu 25 Oct 2007 02:37 AM
VZCZCXYZ0001
RR RUEHWEB
DE RUEHHK #2680 2980237
ZNR UUUUU ZZH
R 250237Z OCT 07
FM AMCONSUL HONG KONG
TO RUCPDOC/USDOC WASHDC
INFO RUEHC/SECSTATE WASHDC 3250
RHMFIUU/HQ BICE WASHINGTON DC
UNCLAS HONG KONG 002680
SIPDIS
USDOC FOR 532/OEA/LHINES/DFARROW
USDOC FOR 3132 FOR FCS/OIO REGIONAL DIRECTOR WILLIAM ZARIT
BICE FOR OFFICE OF STRATEGIC INVESTIGATIONS
SIPDIS
E.O. 12958: N/A
TAGS: BMGT BEXP HK ETRD ETTC
SUBJECT: EXTRANCHECK: PRE-LICENSE CHECK: NEW A-IKOR LIMITED
REF: A) USDOC 09155 B) D384167
1. Unauthorized disclosure of the information provided below is
prohibited by Section 12C of the Export Administration Act.
2. As per reftel A request and at the direction of the Office of
Enforcement Analysis (OEA) of the USDOC Bureau of Industry and
Security (BIS), Export Control Officer Philip Ankel (ECO), conducted
a pre-license check at New A-Ikor Limited, 3/F, HKIB, 2
Biotechnology Avenue, Tai Po Raod, Shatin, Hong Kong (A-Ikor). The
purpose of the visit was to determine the suitability of A-Ikor to
be a recipient of membrane filtration cassettes that are the subject
of export license application D384167. The items (ECCN 2B352) are
valued at USD $11,000 and are controlled for chemical and biological
weapons reasons (CB). The license applicant is Pall Corporation of
East Hills, New York.
3. On October 17, 2007, ECO visited New A-Ikor at the address listed
above and met with Mr. Bing Lou Wong, Chief Technical Officer.
According to Mr. Wong, the company was established in 2007 and is
involved in the bio-pharmaceutical industry with a focus on oxygen
therapeutic products. It has gained exclusive worldwide
manufacturing rights to U.S. company Ikor Inc.'s oxygen therapeutics
(more information on the U.S. entity is available at
www.ikorlife.com). New A-Ikor owns a biologics manufacturing plant
in Hong Kong (that it recently acquired from Advantek Biologics (HK)
Limited). More information concerning A-Ikor is available at
www.aikor.com.
4. Mr. Wong stated that the membrane filtration cassettes would be
used in the production of hemoglobin replacement therapies
(essentially, a replacement hemoglobin delivery mechanism
manufactured with bovine cells). The primary initial market is for
animal use in Europe to treat, for example, dogs that have ingested
rat poison. Mr. Wong provided ECO with a tour of the production
facility, which is located at the address referenced above.
5. At the tie visited, A-Ikor appeared to be a suitable recipient
of the subject controlled items since it cooperated fully with the
PLC and provided substantial information on A-Ikor's proposed use of
the items in Hong Kong. In addition, A-Ikor operates a line a
business that appears consistent with the potential use of the
ordered items. The ECO recommends that this PLC be classified as
Favorable.
Cunningham
View as: DESKTOP | MOBILE © Scoop Media